Vismodegib
- PDF / 169,902 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 34 Downloads / 124 Views
1 S
Various toxicities: 12 case reports In a retrospective analysis of 56 patients treated in hospital in Italy between January 2016 to February 2020, 12 patients (6 women and 6 men) [ages not stated] were described, who developed dysgeusia, muscle pain, muscle spasms, fatigue, gastrointestinal symptoms and hair loss during treatment with vismodegib for locally advanced basal cell carcinoma [route not stated]. The patients, who had locally advanced basal cell carcinoma localised at central face (5 patients), ear (3 patients), periocular region (1 patient) or at multiple locations (3 patients), started receiving treatment with vismodegib 150 mg/day (9 patients) or vismodegib 150mg once every second day (3 patients; prophylactic reduced dose initiation group). Subsequently, the patients developed adverse effects secondary to vismodegib treatment including degree (grade) 1–3 [not all degrees stated] dysgeusia and muscle pain (1 patient), dysgeusia, muscle pain and hair loss (1 patient), muscle spasms, fatigue and gastrointestinal symptoms (2 patient), dysgeusia and muscle spasms (5 patients), fatigue, weight loss and muscle spasms (1 patient), hair loss (1 patient) and dysgeusia (1 patient) [durations of treatment to reactions onsets and outcomes not stated]. Thus, the dose was reduced in 9 patients, of which the treatment was later discontinued later in 3 patients due to the adverse effects. Six patients had a complete response to the treatment and six had partial response to the treatment with vismodegib. Villani A, et al. Reply to: "Comparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma (laBCC) and basal cell nevus syndrome: A retrospective case series". Journal of the American Academy of Dermatology 83: e201-e202, No. 3, Sep 2020. Available from: URL: http:// 803499284 doi.org/10.1016/j.jaad.2020.03.124
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
